2025-02-21 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0. Key Figures Overview:**

JNJ's cumulative return significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ showed a 33.02% return, VOO achieved a 121.84% return, resulting in a substantial negative divergence.  Recent price movement indicates upward momentum, but long-term prospects remain uncertain given the negative expected return.

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.

* **JNJ Cumulative Return:** 33.02%
* **VOO (S&P 500) Cumulative Return:** 121.84%
* **Return Difference:** -88.8% (Relative Divergence: 8.7%)  JNJ significantly underperformed the S&P 500.  The relative divergence indicates that this underperformance is relatively low compared to the historical range of divergence between the two.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 277.3 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.1 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 305.7 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 338.8 |
| 2019-2021  | 28.0% | 7.9% | -43.0% | 0.4 | 377.6 |
| 2020-2022  | 17.0% | 7.9% | 9.0% | 0.4 | 400.1 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 365.8 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 348.2 |
| 2023-2025  | -6.0% | 8.0% | -68.0% | 0.3 | 375.9 |

The data shows inconsistent performance, with periods of strong CAGR followed by periods of negative returns.  Alpha values are generally low, suggesting the stock's performance hasn't significantly outperformed the market, especially in recent years.  Beta is generally around 0.4 indicating lower than average volatility compared to the market.


**2. Recent Price Movement:**

* **Closing Price:** 156.15
* **5-Day Moving Average:** 155.81
* **20-Day Moving Average:** 151.95
* **60-Day Moving Average:** 149.26

The price is above all three moving averages, suggesting a short-term uptrend.

**3. Technical Indicators:**

* **RSI:** 59.39 (Slightly above neutral; not overbought)
* **PPO:** 0.29 (Positive, indicating bullish momentum)
* **20-Day Relative Divergence Change:** -0.7 (Slight negative divergence)
* **Expected Return (2+ years):** -302.0% (Significant negative expected return relative to the S&P 500). This suggests a considerable underperformance risk for long-term investors compared to the market index.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue         |
|------------|--------|-----------------|
| 2024-10-23 | 1.12   | 22.47 B$        |
| 2024-07-25 | 1.95   | 22.45 B$        |
| 2024-05-01 | 1.35   | 21.38 B$        |
| 2024-02-16 | 1.68   | 21.39 B$        |
| 2023-10-27 | 10.32  | 21.35 B$        |

EPS shows considerable fluctuation. The outlier of 10.32 EPS in Oct 2023 needs further investigation to understand if this is due to one-time events or a structural change.  Revenue is relatively stable.

**5. Financial Information:**

No 'Total Revenue' or 'Gross Profit' data is available. This lack of crucial financial data significantly limits the depth of the analysis.  Further data is needed to conduct a comprehensive evaluation.

**6. Overall Analysis:**

JNJ's recent price action shows some short-term positive momentum, but its long-term performance relative to the S&P 500 is severely lagging, with a projected negative return significantly below the market.  The lack of detailed financial data and inconsistent earnings data make it difficult to provide a definitive assessment.  The -302% expected return relative to the S&P 500 is a serious red flag, suggesting a potentially high-risk investment.  Further investigation into the reasons behind the underperformance, particularly the outlier in Q4 2023 earnings, and obtaining complete financial data are crucial before making any investment decisions.
